Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Short term Debt: 2010-2024

Historic Short term Debt for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $1.1 million.

  • China Pharma Holdings' Short term Debt rose 87.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 87.75%. This contributed to the annual value of $1.1 million for FY2024, which is 0.99% up from last year.
  • As of FY2024, China Pharma Holdings' Short term Debt stood at $1.1 million, which was up 0.99% from $1.1 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Short term Debt registered a high of $4.3 million during FY2021, and its lowest value of $1.1 million during FY2023.
  • Over the past 3 years, China Pharma Holdings' median Short term Debt value was $1.1 million (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, China Pharma Holdings' Short term Debt spiked by 112.38% in 2021 and then plummeted by 53.55% in 2023.
  • Over the past 5 years, China Pharma Holdings' Short term Debt (Yearly) stood at $2.0 million in 2020, then soared by 112.38% to $4.3 million in 2021, then crashed by 43.61% to $2.4 million in 2022, then tumbled by 53.55% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024.